TCL053
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →
Ionizable lipid for LNP and nucleic-acid delivery research.
KT-001 is a novel ionizable cationic lipid developed by Vivas, Inc., disclosed in US 2026/0007612 A1 (published Jan 8, 2026).KT-001 demonstrates exceptional skeletal muscle targeting and low liver toxicity.Unlike traditional lipids that primarily accumulate in the liver, KT-001 avoids serum ApoE binding, preventing hepatic uptake. Upon intramuscular injection, it achieves a 29-fold reduction in liver off-target expression compared to standard lipids, while maintaining robust, long-lasting protein expression at the injection site.Its optimized pKa enables precise, pH-responsive endosomal escape for high transfection efficiency. KT-001 is an ideal carrier for localized mRNA vaccines and targeted therapeutics for muscle-related disorders.
| CAS No. | Not available |
| Chemical Name | KT-001 |
| Synonyms | KT001;KT 001 |
| SMILES | CCCCCCCCCC1(CCCCCC)OCC(CCCCN(CCCCO)CCCCC2COC(CCCCCC)(CCCCCCCCC)O2)O1 |
| Formula | C48H95O5N |
| M.Wt | 766.29 |
| Purity | >98% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 13.0499 mL | 2.6100 mL | 1.3050 mL |
| 25 mg | 32.6247 mL | 6.5249 mL | 3.2625 mL |
| 50 mg | 65.2494 mL | 13.0499 mL | 6.5249 mL |
| 100 mg | 130.4989 mL | 26.0998 mL | 13.0499 mL |
| 250 mg | 326.2472 mL | 65.2494 mL | 32.6247 mL |
Contact our team with the catalog number and requested quantity.